A method for inhibiting the activation of mitogen-activated protein kinase (MAPK) signaling pathway in a neuroglial cell of a subject in need, comprising administering to the subject an effective amount of an active ingredient, wherein the active ingredient is selected from a group consisting of a compound of formula (I), a pharmaceutically acceptable ester of the compound of formula (I), and combinations thereof: